E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pain and discomfort during dental treatment in patients with periodontitis |
Smerte og ubehag ved tandrensning hos patienter med parodontitis |
|
E.1.1.1 | Medical condition in easily understood language |
Pain and discomfort during dental treatment in patients with chronic gingivitis |
Smerte og ubehag ved tandrensning hos patienter med kronisk tandkødsbetændelse |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10009102 |
E.1.2 | Term | Chronic periodontitis |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate that the effect of the lozenge is not worse than the effect of the injection during subgingival depuration |
At påvise at sugetabletten ikke har en dårligere lokalbedøvende effekt i forhold til injektionen ved subgingival depuration |
|
E.2.2 | Secondary objectives of the trial |
The patient evaluates
- the pharmaceutical form of the two local anesthetic
- the taste and texture of the lozenge
The dentist evaluates the depuration |
Patienten vurderer
- dispenseringsformen af de to lokalbedøvelser
- smag og konsistens af sugetabletten
Tandlægen vurderer depurationen
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients diagnosed as having, respectively periodontitis marginalis adulta progressiva lenta and periodontitis marginalis adulta progressiva rapid in the hygiene phase, where depurations are repeated within a short timeframe
- Age between 18 and 80 years
- Ability to speak, read and understand danish
- Ability to give oral and written consent |
- Patienter diagnosticeret med hhv. parodontitis marginalis adulta progressiva lenta og parodontitis marginalis adulta progressiva rapida i hygiejnefasen, hvor depurationer gentages indenfor en kort tidsramme
- Alder over 18 år
- Skal være i stand til at tale, læse og forstå dansk
- Skal være informeret mundtligt og have afgivet skriftligt samtykke, samt underskrevet fuldmagtserklæring |
|
E.4 | Principal exclusion criteria |
-Known allergy to bupivacaine or other local anaesthetics of the amide type
-Other gingival infections (eg lichen planus)
-Pregnancy -if in doubt a pregnancy test will be made
-Breastfeeding
|
-Kendt allergi overfor bupivacain eller andre lokalanalgetika af amidtypen.
-Andre gingivale infektioner (fx lichen planus)
-Graviditet. Ved tvivl udføres en graviditetstest.
-Ammende.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
To demonstrate that the effect of the lozenge is not worse than the effect of the injection during subgingival depuration
The patient scores the level of pain by:
-Visual Analog Scale (VAS) 0-10 where 0 = no pain, 10 = extreme pain.
-McGills Pain Questionnaire (MPQ), which gives a qualitative pain profile.
The patient scores the level of discomfort by:
-Visual Analog Scale (VAS) 0-10 where 0 = no discomfort, 10 = extreme discomfort. |
Det primære effektmål er at påvise at sugetabletten ikke har en dårligere lokalbedøvende effekt i forhold til injektionen ved subgingival depuration vurderet udfra:
- Patientens smerte målt ved Visuel Analog Skala (VAS) 0-10 hvor 0 = ingen smerte og 10 = ekstrem smerte
- McGills Pain Questionnaire (MPQ) hvor der tegnes en kvalitativ smerteprofil.
- Patientens ubehag målt ved Visuel Analog Skala (VAS) 0-10, hvor 0 = intet ubehag og 10 = ekstremt ubehag.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The patient evaluates pain and discomfort before, during and after the depuration by VAS and MPQ.
|
Patienten vurderer smerte og ubehag før, under og efter depurationen ved VAS og MPQ.
|
|
E.5.2 | Secondary end point(s) |
The patient evaluates
- the pharmaceutical form of the two local anesthetic using a questionnaire
- the taste and texture of the lozenge using a questionnaire
The dentist evaluates the depuration using a questionnaire |
Patienten vurderer
- dispenseringsformen af de to lokalbedøvelser vha. spørgeskema
- smag og konsistens af sugetabletten vha. spørgeskema
Tandlægen vurderer
- depurationen vha. et spørgeskema
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- The patient evaluates the pharmaceutical forms after the depuration
- The patient assesses taste and texture of the lozenge after the depuration
- The dentist evaluates the depuration after the procedure |
- Patienten vurderer dispenseringsformen af de to lokalbedøvelser efter depurationen
- Patienten vurderer smag og konsistens af sugetabletten efter depurationen
- Tandlægen vurderer depurationen efter proceduren
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Optimization of the anesthetic method when performing a subgingival depuration |
Optimering af bedøvelsesmetoden ved subgingival depuration |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial ends August 2013 |
Forsøget afsluttes august 2013 |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |